Atritech lands $22m in financing:
This article was originally published in Clinica
Developer of the Watchman left atrial appendage system Atritech has closed a $22m round of financing. This round, which was led by SightLine Partners, brings Atritech's total funding over the last 18 months to $45m. The Plymouth, Minnesota-based firm said it will use the proceeds to complete clinical trials of its lead product, which is designed to prevent patients with atrial fibrillation from suffering a stroke by keeping blood clots from forming in the heart.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.